|Dr. Pier Vincenzo Piazza M.D., Ph.D.||CEO & Director||N/A||N/A||1961|
|Ms. Valérie Scappaticci||Chief Financial Officer||N/A||N/A||N/A|
|Stephanie Monlezun||Chief Operating Officer||N/A||N/A||N/A|
Aelis Farma S.A., a clinical-stage biopharmaceutical company, focuses on the discovery and development of drug candidates for the treatment of unaddressed central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate in Phase 2b clinical trials for use in the treatment of the negative consequences of excessive cannabis use; and AEF0217, a drug candidate in Phase 1 clinical trials for use in the treatment of cognitive impairments due to a hyperactivity of the CB1 receptor, as well as cognitive deficits observed in Down syndrome. The company was incorporated in 2013 and is based in Bordeaux, France.
Aelis Farma S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.